Chronic

New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease

Retrieved on: 
Friday, April 5, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Diagnosis, Pterygium, Disease, Eye, Conjunctiva, Safety, Physician, ASCRS, Air conditioning, Conjunctivitis, Tavarua, Tearing, Contact, Dry, Volunteering, Wind, Efficacy, Ophthalmology, Pollen, Chronic, Irritation, Pharmacokinetics, Vision, HCP, Recurrence, Pharma, Food

“Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.

Key Points: 
  • “Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.
  • As ophthalmologists, we need to listen closely to our patients and coordinate with optometrists to fully understand the impact of pterygium.
  • More information about this trial is available here: Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium .
  • The survey was designed with multiple-choice questions, rating questions and open-ended questions.2

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Retrieved on: 
Tuesday, March 5, 2024
Therapy, EMA, Committee, MAA, FDA, PDUFA, Liver cancer, Cirrhosis, Liver failure, Data, THR, MASH, Chronic, CHMP, Death, Patient, Fibrosis, NASH, Disease, Breakthrough therapy, Fatty liver disease, Development, Priority review, Pharmaceutical industry

NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.

Key Points: 
  • NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.
  • Resmetirom is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH.
  • The clinical development program for resmetirom is comprised of 18 clinical studies supporting the MAA: twelve Phase 1 studies, two Phase 2 studies, and four Phase 3 studies.
  • Without treatment, the disease can lead to cirrhosis, liver failure, liver cancer and premature death,” said Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal.

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Omalizumab, Subcutaneous, CD117, Risk, IND, EMA, FA, Chairperson, Cold urticaria, Therapy, MDS, Chronic, Fanconi anemia, ASH, Annual general meeting, European Medicines Agency, Syndrome, CSU, SVP, Patient, Acute myeloid leukemia, Safety, AML, CTA, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced its recent accomplishments, including the authorization by the European Medicines Agency (EMA) of the Company’s Clinical Trial Applications (CTA) for its Phase 1b/2a trials of briquilimab in CIndU and CSU, and outlined its corporate priorities and anticipated milestones for 2024. Called SPOTLIGHT – “Study (Phase 1b/2a) Of subcuTaneous brIquilimab in patients diaGnosed with cHronic inducible urTicaria” – the CIndU study will evaluate single doses of subcutaneous briquilimab in adult patients with cold urticaria or symptomatic dermographism.

Key Points: 
  • “2023 was a strategically important year for Jasper,” said Ronald Martell, President and Chief Executive Officer of Jasper.
  • “We secured IND clearance and CTA authorization for the Phase 1b/2a BEACON study of briquilimab in CSU and successfully dosed the first patient.
  • Our achievements in 2023 set the stage for a transformational year ahead with multiple key clinical milestones on the horizon across multiple indications.
  • Strengthened the organization with key leadership appointments including Thomas Wiggans as Chairperson of the Board of Directors, Scott Brun, M.D.

Reperio Health Wins Big in 2023, with 500%+ YoY Company Growth Plus Innovative Product Updates to Support Equitable Access to Biometric Health Screenings

Retrieved on: 
Tuesday, December 12, 2023
Health, Diabetes, Health Technology, Practice Management, Fitness & Nutrition, Biotechnology, Global health, Chronic, Vitals Global Healthcare, SHRM, Investment, Work, Medical device, Conference, News, Partnership, Growth

In addition to company growth, Reperio ends the year with more than two dozen new clients that represent over 40,000 contracted screenings, plus major investments in innovative product updates to improve access to biometric health screenings data.

Key Points: 
  • In addition to company growth, Reperio ends the year with more than two dozen new clients that represent over 40,000 contracted screenings, plus major investments in innovative product updates to improve access to biometric health screenings data.
  • Some notable clients include Portland-based employer Bob’s Red Mill , and global health and wellbeing company Vitality Global .
  • Reperio’s partnership with AccessCare Health even took screenings internationally, with thousands of screenings contracted by Workday in the U.K. and Ireland.
  • Given the uptick in screenings in 2023, Reperio focused on innovative product updates that would continue to prioritize the consumer experience.

United States $36.8 Bn Active Pharmaceutical Ingredient Markets, Competition, Forecast and Opportunities, 2018-2022 and 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023
Health, Pharmaceutical, Infection, Research, Conditional sentence, Prevalence, Incidence, Chronic, Patient, API, Therapy, Tablet, Ageing, Growth, Patent, Vaccine, Generic drug, Fine chemical, Cancer, Generic

Rising Prevalence of Cancer: The increasing prevalence of cancer is leading to a higher demand for APIs, particularly for targeted therapies and advanced treatment modalities.

Key Points: 
  • Rising Prevalence of Cancer: The increasing prevalence of cancer is leading to a higher demand for APIs, particularly for targeted therapies and advanced treatment modalities.
  • Advancements in Oncology Drug Research: The sophistication of oncology drug research is driving the development of high-efficacy drugs, increasing the need for specialized APIs.
  • The North-East region of the United States is expected to dominate the API market, primarily due to the presence of leading pharmaceutical companies, research infrastructure, and favorable government policies.
  • Company Profiles: Detailed analysis of the major companies present in the United States Active Pharmaceutical Ingredient Market.

Transamerica Bolsters Long Term Care Planning with Innovative Workplace Life Insurance Rider

Retrieved on: 
Monday, November 27, 2023
Extension, Retirement, Nursing care plan, Safety, Employee benefits, Policy, Chronic condition, Chronic, Life insurance, Transamerica

BALTIMORE, Nov. 27, 2023 /PRNewswire/ -- Transamerica today unveiled its new Long Term Care Rider for the Transamerica Universal Life Insurance SM, a strategic innovation designed to help address the long-term care needs of Americans approaching retirement.

Key Points: 
  • BALTIMORE, Nov. 27, 2023 /PRNewswire/ -- Transamerica today unveiled its new Long Term Care Rider for the Transamerica Universal Life Insurance SM, a strategic innovation designed to help address the long-term care needs of Americans approaching retirement.
  • Transamerica Universal Life Insurance, already a popular choice with the highest participation rate among all of Transamerica's insurance products, is now available with a new living benefit, the Long Term Care Rider.
  • The introduction of our Long Term Care Rider is a vital step towards empowering individuals to manage their long-term care needs proactively."
  • For more information about how Transamerica Universal Life Insurance with the Long Term Care Rider can enhance a workplace benefits strategy, employers may contact their financial professionals.

Global Blood Transfusion Set Market Expected to Rebound with 3.0% CAGR, Reaching $591 Million by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Health, Other Health, Male, IV, Prevalence, ICU Medical, Pump, Baxter, Cancer, Luer, Domination, Research, BD (company), Blood transfusion, Chronic, BD, Medical device, Pharmaceutical industry, Alaris

In 2023, the global blood transfusion set market reported a total value of $480.1 million, experiencing a modest decline of 3.5% from the $464.1 million recorded in 2022.

Key Points: 
  • In 2023, the global blood transfusion set market reported a total value of $480.1 million, experiencing a modest decline of 3.5% from the $464.1 million recorded in 2022.
  • Currently, market leaders in the global blood transfusion set market include Becton Dickinson (BD), Baxter, and ICU Medical.
  • Rebound Expected: The global blood transfusion set market is projected to rebound with a CAGR of 3.0%, reaching a valuation of $591 million, following a 3.5% decline in 2023.
  • Dominant Players: Key players such as Becton Dickinson (BD), Baxter, and ICU Medical currently dominate the global blood transfusion set market.

Global Oral Clinical Nutrition Market Predicted to Expand Significantly by 2028, Driven by Rising Chronic Diseases - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 5, 2023
Health, Other Health, GSK plc, Prevalence, Diabetes, Alzheimer's disease, Bayer, Malnutrition, Health care, Abbott Laboratories, Cardiovascular disease, Cancer, Ageing, Nutrient, Sarcopenia, Competition, Baxter International, Market, Incidence, Danone, Cachexia, Patient, Lijun International Pharmaceutical (Holding) Co. Ltd., Risk, Whey, Conditional sentence, Nutricia, Chronic kidney disease, Intake, Chronic, Nestlé, Wound healing, Dietary supplement, Pharmaceutical industry, Dysphagia, Pfizer

The global oral clinical nutrition market is poised for substantial growth during the forecast period due to the increasing prevalence of chronic diseases and a growing emphasis on patient-centric care.

Key Points: 
  • The global oral clinical nutrition market is poised for substantial growth during the forecast period due to the increasing prevalence of chronic diseases and a growing emphasis on patient-centric care.
  • Additionally, the rise in malnutrition and related conditions like sarcopenia and cachexia is boosting the demand for oral clinical nutrition products.
  • Rising Chronic Diseases: The escalating incidence of chronic conditions such as diabetes, cardiovascular disease, and cancer is a significant driver of the global oral clinical nutrition market.
  • The comprehensive Global Oral Clinical Nutrition Market report covers market segmentation by indication, distribution channel, and region, highlighting industry trends and growth drivers.

CryptoChronic awarded CertiK Security Score placing it in the Top Percentile

Retrieved on: 
Saturday, July 15, 2023
Smoke, GitHub, NFT, CertiK, Formal verification, Blockchain, Ecosystem, AI, Chronic, Trustworthy Repositories Audit & Certification, Safety, Cryptocurrency, Yale University

Currently, CryptoChronic's CertiK Score stands at 68.78, subject to regular fluctuations based on social channel and GitHub activities.

Key Points: 
  • Currently, CryptoChronic's CertiK Score stands at 68.78, subject to regular fluctuations based on social channel and GitHub activities.
  • This places them solidly within the top 20 percentile, ranked at number 2009 among the tens of thousands of crypto projects scrutinized.
  • Relative to other pre-launch indie GameFi projects, this score sets CryptoChronic atop the field.
  • A CertiK certification ensures that blockchain projects meet the highest standards of safety and trustworthiness by verifying their integrity, security, and dependability.

CryptoChronic, Revolutionary NFT Collection and Crypto Game, Launches Next Tuesday

Retrieved on: 
Wednesday, July 12, 2023
Smoke, Chronics, NFT, ETH, Whitelist, Breeding, Central European Time, Non-fungible token, Collection, Love, Fertility, Ecosystem, Chronic, Video game, Weedmaps, Discord

These NFTs are artistically designed digital pet strains of marijuana, each possessing genetic traits that unlock various gameplay features.

Key Points: 
  • These NFTs are artistically designed digital pet strains of marijuana, each possessing genetic traits that unlock various gameplay features.
  • Players can engage in breeding to create new offspring NFTs, manage resources through the "Cannagotchi" system, and participate in player-versus-player battles known as "Smoke-Offs."
  • They are integrated into all game layers, and the game is free to play, benefiting early adopters as the community grows.
  • Concurrently with the NFT collection launch, Chronic Games releases the online version of their full game.